JNJ-42165279
 | |
| Clinical data | |
|---|---|
| ATC code |
|
| Legal status | |
| Legal status | |
| Identifiers | |
| |
| PubChem CID | |
| Chemical and physical data | |
| Formula | C18H17ClF2N4O3 |
| Molar mass | 410.802 g/mol g·mol−1 |
| 3D model (JSmol) | |
| |
JNJ-42165279 is a drug developed by Johnson & Johnson which acts as a potent and selective inhibitor of the enzyme fatty acid amide hydrolase (FAAH), with an IC50 of 70nM.[1] It is described as a covalently binding but slowly reversible selective inhibitor of FAAH.[2] JNJ-42165279 is being developed for the treatment of anxiety and major depressive disorder. Clinical development has progressed as far as Phase II human trials with two studies in patients with mood disorders registered in ClinicalTrials.gov.[3][4]
Following a series of severe adverse events, including a death, in a trial with a different FAAH inhibitor BIA 10-2474, Janssen announced that it was temporarily suspending dosing in its two Phase II clinical trials with JNJ-42165279, headlining the decision as "precautionary measure follows safety issue with different drug in class". Janssen was emphatic that no serious adverse events had been reported in any of the clinical trials with JNJ-42165279 to date. The suspension is to remain in effect until more information is available about the BIA 10-2474 study. [5]
See also
References
- ^ Keith JM, Jones WM, Tichenor M, Liu J, Seierstad M, Palmer JA, Webb M, Karbarz M, Scott BP, Wilson SJ, Luo L, Wennerholm ML, Chang L, Rizzolio M, Rynberg R, Chaplan SR1, Breitenbucher JG. Preclinical Characterization of the FAAH Inhibitor JNJ-42165279. ACS Med Chem Lett. 2015 Nov 2;6(12):1204-8. PMID 26713105 doi: 10.1021/acsmedchemlett.5b00353.
- ^ JNJ-42165279: selective and slowly reversible FAAH inhibitor. Central and Peripheral PK/PD.
- ^ "A Safety and Efficacy Study of JNJ-42165279 in Participants With Social Anxiety Disorder (NCT02432703)". ClinicalTrials.gov Registry. 29 April 2015. Retrieved 21 January 2016.
- ^ "An Efficacy, Safety and Tolerability Study of JNJ-42165279 in Participants With Major Depressive Disorder With Anxious Distress (NCT02498392)". ClinicalTrials.gov Registry. 13 July 2015. Retrieved 21 January 2016.
- ^ "Janssen Research & Development, LLC Voluntarily Suspends Dosing in Phase 2 Clinical Trials of Experimental Treatment for Mood Disorders". Janssen.com. 17 January 2016. Retrieved 21 January 2016.
 | This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it. |